IP Library Granted Patent US 7,288,525
Granted Patent B2
US 7,288,525 · App. 11/321,130 · Granted Oct 30, 2007

Method for lowering serum homocysteine

Assignee: The Research Foundation of State University of New York
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,288,525
App. No.
11/321,130
Granted
Oct 30, 2007
Kind
B2
Abstract

The present invention provides a method for reducing the amount of homocysteine in the blood of an individual. The method comprises administering to the individual a composition comprising a homocysteine lowering agent in an amount effective to lower the amount of homocysteine in the blood of the individual. The homocysteine lowering agent is selected from A dipeptides consisting of isoleucine, leucine, valine, or glycine and combinations thereof; tripeptides consisting of isoleucine, leucine, valine, or glycine and combinations thereof; alpha-ketobutyrate; propionyl A CoA, and combinations thereof.

Claims (15)

1. A method for lowering the amount of homocysteine in the blood of an individual comprising administering to the individual in need thereof an amount of a composition comprising a homocysteine lowering agent effective to lower the amount of homocysteine in the blood of the individual, wherein the agent is selected from the group consisting of:

a) dipeptides consisting of isoleucine, leucine, valine, or glycine, and combinations thereof;

b) tripeptides consisting of isoleucine, leucine, valine, or glycine, and combinations thereof;

c) alpha-ketobutyrate;

d) propionyl CoA; and

e) combinations of a) through d);

wherein the amount of homocysteine in the blood of the individual after administration of the agent is lower in comparison to the amount of homocysteine in the blood of the individual prior to administration of the agent.

2. The method of claim 1 , wherein the dipeptides or tripeptides of a) or b) comprise glycine and are administered in a dosage of from 0.5-5 grams per day.

3. The method of claim 1 , wherein the agent is an L-isoleucine dipeptide.

4. The method of claim 1 , wherein the agent is a dipeptide consisting of L-isoleucine and one of L-valine or L-leucine.

5. The method of claim 1 , wherein the agent is an L-isoleucine tripeptide.

6. The method of claim 1 , wherein the agent is a tripeptide consisting of at least one L-isoleucine and L-leucine or L-valine.

7. The method of claim 1 , wherein the agent is a tripeptide consisting of L-isoleucine, L-leucine and L-valine.

8. The method of claim 1 , wherein the composition is administered orally.

9. The method of claim 1 , wherein the agent is selected from alpha-ketobutyrate and propionyl CoA.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 30, 2024
From: RESEARCH FOUNDATION OF STATE UNIVERSITY OF NY, UNIVERSITY AT BUFFALO
To: NATIONAL INSTITUTES OF HEALTH
Reel/Frame 068122/0527 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2007
From: GUTTUSO, THOMAS, JR.
To: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
Reel/Frame 019721/0915 →
Continuity (2)
Provisional Application 6063984600 · Dec 28, 2004
Related Publication 20060252699A1 · Nov 9, 2006